Recercat. Dipósit de la Recerca de Catalunya
Publication
Artículo científico (JournalArticle)
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer
Cancer; DNA damage; Omomyc, Càncer; Dany a l'ADN; Omomyc, Cáncer; Daño en el ADN; Omomyc, MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA repair. Here, we show that Omomyc, the only direct MYC inhibitor that has completed a phase 1 trial, shuts down DDR genes in triple-negative breast cancer (TNBC), causing DDR defects and inducing DNA damage. Since DDR-deficient tumors are currently targeted by poly ADP-ribose polymerase inhibitors (PARPis), we tested combinations with Omomyc. We show that Omomyc-induced DNA damage is enhanced by PARPis and that the inhibitors cooperate even in models with intrinsic or acquired PARPi resistance, both in vitro and in vivo. Moreover, using patient-derived models and clinical samples, we reveal a role for MYC as a predictor of PARPi resistance. Overall, our research highlights the opportunity of combining MYC inhibition by Omomyc with PARPis in PARPi-resistant TNBC, where MYC transcriptional activity represents a predictive biomarker of resistance to therapy., We acknowledge the kind support from the Vall d’Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – F.G., PFIS doctoral bursary); Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1 and Líneas Estratégicas PLEC2021-007959); Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509); EDIReX (H2020 INFRAIA 731105-2); the European Research Council (ERC-2023-ADG 101142260); the Spanish Ministry of Science and Innovation and the European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808); and the Fero Foundation for funding support.